药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Cinolazepam
Tecemotide
The therapeutic efficacy of Tecemotide can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Bacillus calmette-guerin substrain danish 1331 live antigen
The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Hepatitis B Vaccine (Recombinant)
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Human rabies virus immune globulin
The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Typhoid Vaccine Live
The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Anthrax vaccine
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Hepatitis A Vaccine
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Yellow Fever Vaccine
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Bacillus calmette-guerin substrain connaught live antigen
The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Typhoid Vi polysaccharide vaccine
The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Clostridium tetani toxoid antigen (formaldehyde inactivated)
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Hydrocortisone butyrate.